Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Taysha Gene Therapies, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344610
| Line item | For the three months ended June 30, 2026 | For the three months ended June 30, 2025 | For the six months ended June 30, 2026 | For the six months ended June 30, 2025 |
|---|---|---|---|---|
| Revenue | — | $1,986 | — | $4,288 |
| Operating expenses: | ||||
| Research and development | 38,636 | 20,141 | 72,445 | 35,706 |
| General and administrative | 12,146 | 8,598 | 21,823 | 16,756 |
| Net gain on lease termination | (3,433) | — | (3,433) | — |
| Total operating expenses | 47,349 | 28,739 | 90,835 | 52,462 |
| Loss from operations | (47,349) | (26,753) | (90,835) | (48,174) |
| Other income (expense): |
Item 1. Financial Statements.
FAQ
- What is Taysha Gene Therapies, Inc.'s R&D?
- Taysha Gene Therapies, Inc. (TSHA) reported R&D of $38.64M in Q2 2026.
- How has Taysha Gene Therapies, Inc.'s R&D changed year-over-year?
- Taysha Gene Therapies, Inc.'s R&D increased by 91.8% year-over-year, from $20.14M to $38.64M.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s R&D?
- Over 4 years (2021 to 2025), Taysha Gene Therapies, Inc.'s R&D has grown at a -10.0% compound annual growth rate (CAGR), from $131.94M to $86.4M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Taysha Gene Therapies, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude